Reshaping the HIV treatment and prevention landscape
Innovative early programmes plus continued business
development offer potential for sustained growth beyond 2026
Infectious Diseases
GSK'868 (P14kẞ inhibitor)
for viral COPD exacerbations
Phlb start 2022
HBV therapeutic vaccine
for hepatitis B
POC anticipated 2023
MenABCWY 2nd gen
for meningitis
Phl start 1H 2021
HIV
Oncology
GSK'109 bnAb
Phll start 1H 2021
Synthetic lethality
MAT2A (Phl started 1H 2021),
Pol Theta, Werner Helicase
Immunology / Respiratory
GSK'279 (anti-CCL17)
for osteoarthritis pain
Phlb data 2022
NRTTI
Phl start 2H 2021
GSK'347 (FiMH)
for uUTI
Phlb start 2022
Capsid inhibitor
Phl start 1H 2022
LA maturation inhibitor
Phl start 1H 2022
CD226 axis
(CD96, TIGIT, PVRIG)
Immuno-oncology
Jemperli*
LAG-3*, TIM-3*, STING
Novel target for
multiple sclerosis
Phl start 2H 2021
Novel target for
atopic dermatitis
Phlb start 2H 2021
Cell Therapy
next generation
GSK'393 (TG2 inhibitor)
for celiac disease
Phll start 2022
Business Development focused on human genetics and the science of the immune system
HBV hepatitis B virus; MS multiple sclerosis; LA long acting; bnAb broadly neutralising antibody
*Tesaro asset
gsk
53View entire presentation